Page last updated: 2024-12-05

chlorphentermine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chlorphentermine is a synthetic anorectic drug that was marketed in the 1970s as an appetite suppressant. It acts as a stimulant and a sympathomimetic agent, causing the release of norepinephrine and dopamine in the brain, which can lead to feelings of euphoria and increased energy. However, chlorphentermine was withdrawn from the market in the 1970s due to concerns about its potential for cardiovascular toxicity, including the risk of pulmonary hypertension and valvular heart disease. The drug is still studied in research settings for its potential therapeutic applications, particularly in the treatment of obesity and other metabolic disorders. Recent research has focused on the use of chlorphentermine as a potential treatment for Parkinson's disease, as it has been shown to improve motor function in animal models. Further research is needed to determine its long-term safety and efficacy in humans.'

Chlorphentermine: A sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of DEXTROAMPHETAMINE. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10007
CHEMBL ID1201269
CHEBI ID3646
SCHEMBL ID160516
SCHEMBL ID11577478
MeSH IDM0004194

Synonyms (70)

Synonym
BB 0259200
phenethylamine, p-chloro-.alpha.,.alpha.-dimethyl-
benzeneethanamine, 4-chloro-.alpha.,.alpha.-dimethyl-
1-(4-chlorophenyl)-2-methylpropan-2-amine
einecs 207-314-9
teramine
hsdb 3303
chlorphentermine [inn:ban]
lucofen sa
clorfentermina [inn-spanish]
brn 1099928
effox
desopimon
beta-(p-chlorophenyl)-alpha,alpha-dimethylethylamine
4-chloro-alpha,alpha-dimethylphenethylamine
1-(p-chlorophenyl)-2-methyl-2-aminopropane
4-chloro-alpha,alpha-dimethylbenzeneethanamine
benzeneethanamine, 4-chloro-alpha,alpha-dimethyl-
clorfentermina
dea no. 1645
phenethylamine, p-chloro-alpha,alpha-dimethyl-
p-chloro-alpha,alpha-dimethylphenethylamine
1-(p-chlorophenyl)-2-methyl-2-propylamine
chlorphenterminum [inn-latin]
alpha,alpha-dimethyl-p-chlorophenethylamine
CHEMDIV2_002573
EU-0053624
chlorphentermine
C07559
461-78-9
NCGC00160422-01
4-chloro-a,a-dimethylbenzeneethanamine
a,a-dimethyl-p-chlorophenethylamine
DB01556
4-chloro-a,a-dimethylphenethylamine
OPREA1_632031
HMS1376E21
STK664067
unii-nhw07912o7
chlorphenterminum
nhw07912o7 ,
4-12-00-02823 (beilstein handbook reference)
CHEMBL1201269
chebi:3646 ,
nsc_10007
bdbm85704
cas_461-78-9
AKOS005535680
chlorphenteramine
chlorophentermine
FT-0683062
AB02276
p-chloro-.alpha.,.alpha.-dimethylphenethylamine
chlorphentermine [mi]
chlorphentermine [who-dd]
benzeneethanamine, 4-chloro-.alpha.,.alpha.-dimethyl
chlorphentermine [hsdb]
chlorphentermine [inn]
1,1-dimethyl-2-(4-chlorophenyl)ethylamine
SCHEMBL160516
4-chloro-.alpha.,.alpha.-dimethylbenzeneethanamine
1-(4-chlorophenyl)-2-methyl-2-propanamine #
.beta.-(p-chlorophenyl)-.alpha.,.alpha.-dimethylethylamine
4-chloro-.alpha.,.alpha.-dimethylphenethylamine
lucofen (salt/mix)
SCHEMBL11577478
DTXSID0022806
Q5103230
2-(4-chloro-phenyl)-1,1-dimethyl-ethylamine
mfcd00055368

Research Excerpts

Overview

Chlorphentermine (CP) is a cationic, amphiphilic drug. It has been studied widely for its ability to induce phospholipidosis.

ExcerptReferenceRelevance
"Chlorphentermine (CP) is a cationic, amphiphilic drug (CAD) that has been studied widely for its ability to induce phospholipidosis, a disorder characterized by excessive accumulation of cellular phospholipid and ultrastructural development of lysosomal lamellar bodies (LLBs) in the cell. "( In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.
Beard, TL; Kacew, S; McCloud, CM; Reasor, MJ, 1995
)
2
"Chlorphentermine is a cationic amphiphilic drug which produces a phospholipid storage disorder in rat lungs. "( Alterations in rat alveolar surfactant phospholipids and proteins induced by administration of chlorphentermine.
Bowman, L; Miles, PR; Reasor, MJ; Tucker, J; Wright, JR, 1986
)
1.93

Effects

Chlorphentermine (CP) has been noted to cause primary pulmonary hypertension both clinically and experimentally. It has been shown to inhibit the uptake and metabolism of 5-HT.

ExcerptReferenceRelevance
"Chlorphentermine (CP) has been noted to cause primary pulmonary hypertension both clinically and experimentally. "( Effect of chlorphentermine on the pulmonary disposition of norepinephrine in the isolated perfused rabbit lung.
Angevine, LS; Ho, IK; Mehendale, HM; Nabeshima, T, 1981
)
2.11
"Chlorphentermine has been shown to inhibit the uptake and metabolism of 5-HT."( The effect of fenfluramine on the pulmonary disposition of 5-hydroxytryptamine in the isolated perfused rat lung: a comparison with chlorphentermine.
Syce, JA; Valodia, P, 2000
)
1.23

Dosage Studied

ExcerptRelevanceReference
" When subchronically fed to rats at a daily dosage of approximately 180 mg/kg, amantadine induced ultrastructural symptoms of generalized lipidosis, the degree of which was, however, by far less marked than that previously reported for chlorphentermine."( Amantadine-induced lipidosis. A cytological and physicochemical study.
Burmester, J; Hanpft, R; Kröplin, K; Lüllmann-Rauch, R; Patten, M, 1987
)
0.46
" Treatment with the high dosage caused a significant reduction of creatinine clearance and significant impairment of both abilities to concentrate and to dilute the urine."( Impairment of renal function in rats with generalized lipidosis as induced by chlorphentermine.
Lüllmann, H; Lüllmann-Rauch, R; Mösinger, EU, 1981
)
0.49
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID643383Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID540240Phospholipidosis-positive literature compound observed in rabbit
AID540237Phospholipidosis-positive literature compound observed in rat
AID540238Phospholipidosis-positive literature compound observed in mouse
AID540239Phospholipidosis-positive literature compound observed in dog
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (296)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990274 (92.57)18.7374
1990's12 (4.05)18.2507
2000's4 (1.35)29.6817
2010's4 (1.35)24.3611
2020's2 (0.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.44 (24.57)
Research Supply Index5.78 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (3.18%)5.53%
Reviews18 (5.73%)6.00%
Case Studies1 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other285 (90.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]